Edition:
United Kingdom

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

100.75EUR
2:47pm GMT
Change (% chg)

€-2.05 (-1.99%)
Prev Close
€102.80
Open
€102.75
Day's High
€102.75
Day's Low
€99.58
Volume
49,003
Avg. Vol
101,240
52-wk High
€129.85
52-wk Low
€64.81

Select another date:

Wed, Nov 29 2017

BRIEF-Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​

* ‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​

BRIEF-Ipsen ‍reports Q3 2017 group sales growth of 22.6%​

* Q3 GROUP SALES EUR ‍​470.1 MILLION VERSUS EUR 390.6 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Ipsen announces success of phase 3 CELESTIAL trial of Cabozantinib

* IPSEN ANNOUNCES THAT PHASE 3 CELESTIAL TRIAL OF CABOZANTINIB MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

BRIEF-Ipsen receives approval from European Commission for Xermelo

* Ipsen receives approval from European Commission for Xermelo® (Telotristat Ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

BRIEF-FDA approves new indication for Ipsen's somatuline depot injection

* U.S. FDA approves new indication for Ipsen's somatuline® depot (lanreotide) injection for the treatment of carcinoid syndrome Source text for Eikon: Further company coverage:

BRIEF-Ipsen annouces US FDA approval of new indication for Somatuline Depot

* U.S. FDA APPROVES NEW INDICATION FOR IPSEN'S SOMATULINE DEPOT (LANREOTIDE) INJECTION FOR THE TREATMENT OF CARCINOID SYNDROME Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial

* ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

Pharma group Ipsen raises margin target after strong H1

July 27 French pharmaceutical group Ipsen raised its annual margin target on Thursday on the back of a strong first half, boosted by its core speciality care business which includes oncology and endocrinology products.

BRIEF-Ipsen delivers H1 sales growth of 18.8%, upgrades its FY 2017 guidance

* IPSEN DELIVERS STRONG SALES GROWTH OF 18.8% IN THE FIRST HALF OF 2017 AND UPGRADES ITS GUIDANCE FOR FULL YEAR 2017

BRIEF-Ipsen receives positive CHMP opinion for approval of Cermelo

* Ipsen receives positive CHMP opinion for approval of Xermelo® (telotristat ethyl), for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy Source text for Eikon: Further company coverage:

Select another date: